Piper Sandler Maintains Overweight Rating for Ocular Therapeutix: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Piper Sandler has reaffirmed its Overweight rating on Ocular Therapeutix (NASDAQ:OCUL) and increased its price target from $10.00 to $15.00. Ocular Therapeutix's shares have risen 1.22% in the last 24 hours to $9.98. The new price target suggests a potential 50.3% increase from the current price. Ocular Therapeutix is a biotech company focusing on eye disease therapies using its hydrogel platform technology.
February 26, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler maintains Overweight rating on Ocular Therapeutix, raising price target from $10 to $15. Shares currently at $9.98, indicating a potential 50.3% increase.
The reaffirmation of the Overweight rating and the increase in price target by Piper Sandler are strong positive signals for Ocular Therapeutix. Given the company's innovative approach to eye disease treatment and the potential for its pipeline products, this analyst endorsement could lead to increased investor confidence and a rise in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100